GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A1334 Mosapride CitrateTarget: 5-HT3 Receptors|5-HT4 ReceptorsSummary: 5-HT receptor agonist -
A5010 AsenapineSummary: Inhibits adrenergic receptor/5-HT receptor -
A2884 Doxazosin MesylateSummary: α1-adrenergic receptor antagonist -
A2436 Fluoxetine HCl1 CitationTarget: Serotonin (5-HT) reuptakeSummary: Serotonin reuptake inhibitor,selective -
A2553 Fluvoxamine maleateSummary: Serotonin reuptake inhibitor,selective,antidepressant -
A1748 Ramelteon1 CitationTarget: Melatonin ReceptorsSummary: Agonist of melatonin receptor(M1-M2),highly selective -
A1987 Ki164256 CitationTarget: LPA ReceptorsSummary: LPA receptor antagonist -
A5318 Prazosin HClSummary: α1 and α2B-adrenoceptor antagonist -
A5375 TranilastSummary: Angiogenesis inhibitor -
A5355 Venlafaxine HClSummary: Dual serotonin/noradrenalin re-uptake inhibitor
